These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 17011981)

  • 1. Fluorescence in situ hybridization studies using BAC clones of the EVI1 locus in hematological malignancies with 3q rearrangements.
    Madrigal I; Carrió A; Gómez C; Rozman M; Esteve J; Nomdedeu B; Campo E; Costa D
    Cancer Genet Cytogenet; 2006 Oct; 170(2):115-20. PubMed ID: 17011981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An interphase fluorescence in situ hybridisation assay for the detection of 3q26.2/EVI1 rearrangements in myeloid malignancies.
    Bobadilla D; Enriquez EL; Alvarez G; Gaytan P; Smith D; Slovak ML
    Br J Haematol; 2007 Mar; 136(6):806-13. PubMed ID: 17341266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interphase fluorescence in situ hybridization assay for the detection of rearrangements of the EVI-1 locus in chromosome band 3q26 in myeloid malignancies.
    Wieser R; Schreiner U; Rieder H; Pirc-Danoewinata H; Grüner H; Loncarevic IF; Fonatsch C
    Haematologica; 2003 Jan; 88(1):25-30. PubMed ID: 12551823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements.
    Poppe B; Dastugue N; Vandesompele J; Cauwelier B; De Smet B; Yigit N; De Paepe A; Cervera J; Recher C; De Mas V; Hagemeijer A; Speleman F
    Genes Chromosomes Cancer; 2006 Apr; 45(4):349-56. PubMed ID: 16342172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conventional cytogenetics and breakpoint distribution by fluorescent in situ hybridization in patients with malignant hemopathies associated with inv(3)(q21;q26) and t(3;3)(q21;q26).
    De Braekeleer E; Douet-Guilbert N; Basinko A; Bovo C; Guéganic N; Le Bris MJ; Morel F; De Braekeleer M
    Anticancer Res; 2011 Oct; 31(10):3441-8. PubMed ID: 21965759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EVI1 overexpression in t(3;17) positive myeloid malignancies results from juxtaposition of EVI1 to the MSI2 locus at 17q22.
    De Weer A; Speleman F; Cauwelier B; Van Roy N; Yigit N; Verhasselt B; De Moerloose B; Benoit Y; Noens L; Selleslag D; Lippert E; Struski S; Bastard C; De Paepe A; Vandenberghe P; Hagemeijer A; Dastugue N; Poppe B;
    Haematologica; 2008 Dec; 93(12):1903-7. PubMed ID: 18815193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amplification and translocation of 3q26 with overexpression of EVI1 in Fanconi anemia-derived childhood acute myeloid leukemia with biallelic FANCD1/BRCA2 disruption.
    Meyer S; Fergusson WD; Whetton AD; Moreira-Leite F; Pepper SD; Miller C; Saunders EK; White DJ; Will AM; Eden T; Ikeda H; Ullmann R; Tuerkmen S; Gerlach A; Klopocki E; Tönnies H
    Genes Chromosomes Cancer; 2007 Apr; 46(4):359-72. PubMed ID: 17243162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.
    Haferlach C; Bacher U; Grossmann V; Schindela S; Zenger M; Kohlmann A; Kern W; Haferlach T; Schnittger S
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1079-85. PubMed ID: 22887804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel chromosomal translocation t(3;7)(q26;q21) in myeloid leukemia resulting in overexpression of EVI1.
    Storlazzi CT; Anelli L; Albano F; Zagaria A; Ventura M; Rocchi M; Panagopoulos I; Pannunzio A; Ottaviani E; Liso V; Specchia G
    Ann Hematol; 2004 Feb; 83(2):78-83. PubMed ID: 14551738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer.
    Nanjundan M; Nakayama Y; Cheng KW; Lahad J; Liu J; Lu K; Kuo WL; Smith-McCune K; Fishman D; Gray JW; Mills GB
    Cancer Res; 2007 Apr; 67(7):3074-84. PubMed ID: 17409414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute panmyelosis with myelofibrosis with EVI1 amplification.
    Grygalewicz B; Woroniecka R; Pastwińska A; Rygier J; Krawczyk P; Borg K; Makuch-Łasica H; Patkowska E; Pieńkowska-Grela B
    Cancer Genet; 2012 May; 205(5):255-60. PubMed ID: 22682625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities.
    Baldazzi C; Luatti S; Zuffa E; Papayannidis C; Ottaviani E; Marzocchi G; Ameli G; Bardi MA; Bonaldi L; Paolini R; Gurrieri C; Rigolin GM; Cuneo A; Martinelli G; Cavo M; Testoni N
    Genes Chromosomes Cancer; 2016 Apr; 55(4):375-88. PubMed ID: 26815134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breakpoint heterogeneity in (2;3)(p15-23;q26) translocations involving EVI1 in myeloid hemopathies.
    De Braekeleer M; Guéganic N; Tous C; Le Bris MJ; Basinko A; Morel F; Douet-Guilbert N
    Blood Cells Mol Dis; 2015 Feb; 54(2):160-3. PubMed ID: 25486926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant EVI1 expression in acute myeloid leukemias associated with the t(3;8)(q26;q24).
    Lennon PA; Abruzzo LV; Medeiros LJ; Cromwell C; Zhang X; Yin CC; Kornblau SM; Konopieva M; Lin P
    Cancer Genet Cytogenet; 2007 Aug; 177(1):37-42. PubMed ID: 17693189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia.
    Balgobind BV; Lugthart S; Hollink IH; Arentsen-Peters ST; van Wering ER; de Graaf SS; Reinhardt D; Creutzig U; Kaspers GJ; de Bont ES; Stary J; Trka J; Zimmermann M; Beverloo HB; Pieters R; Delwel R; Zwaan CM; van den Heuvel-Eibrink MM
    Leukemia; 2010 May; 24(5):942-9. PubMed ID: 20357826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of translocational breakpoints within the intron region before the last coding exon (exon 12) of the EVI1 gene in two cases of CML-BC with inv(3)(q21q26).
    Suzukawa K; Taki T; Abe T; Asoh H; Kamada N; Yokota J; Morishita K
    Genomics; 1997 Jun; 42(2):356-60. PubMed ID: 9192861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains.
    Redon R; Muller D; Caulee K; Wanherdrick K; Abecassis J; du Manoir S
    Cancer Res; 2001 May; 61(10):4122-9. PubMed ID: 11358835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemia.
    Vinatzer U; Mannhalter C; Mitterbauer M; Gruener H; Greinix H; Schmidt HH; Fonatsch C; Wieser R
    Genes Chromosomes Cancer; 2003 Jan; 36(1):80-9. PubMed ID: 12461752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a dual-color, double fusion FISH assay to detect RPN1/EVI1 gene fusion associated with inv(3), t(3;3), and ins(3;3) in patients with myelodysplasia and acute myeloid leukemia.
    Shearer BM; Sukov WR; Flynn HC; Knudson RA; Ketterling RP
    Am J Hematol; 2010 Aug; 85(8):569-74. PubMed ID: 20556821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytogenetics and fluorescence in-situ hybridization in detection of hematological malignancies.
    Frenny VJ; Antonella Z; Luisa A; Shah AD; Sheth JJ; Rocchi M
    Indian J Cancer; 2003; 40(4):135-9. PubMed ID: 14716109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.